Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Risedronate in Glucocorticoid-induced Osteoporosis
NCT01575873Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2012
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of denosumab in glucocorticoid-induced osteoporosis (GIOP), sponsored by Amgen. Started Mar 2012; status: completed.
02
Drugs
denosumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT01575873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01575873.